Analyzing Safety Data

  • J. Rick Turner
Part of the SpringerBriefs in Pharmaceutical Science & Drug Development book series (BRIEFSPSDD)


The safety of a drug is assessed at all stages of its life cycle, from drug discovery through nonclinical development, preapproval clinical development, and all the time it is subsequently on the market. The focus of this chapter is safety assessment during later-stage clinical trials. When a drug is granted marketing approval by a regulatory agency and therefore becomes available to prescribing physicians and their patients, the best available information upon which the doctor and patient can form answers to questions concerning the drug’s safety profile is the safety information gathered during clinical trials. This information is provided to the clinician and all patients receiving the drug in the drug’s package insert, or label. The content of the label will have been agreed upon by the Sponsor and the regulatory agency granting marketing approval, and it summarizes the best available data about the drug’s safety at that point in time.


Drug safety Adverse events Adverse drug reaction Exclusion of unacceptable risk Antidiabetic drugs Risk ratio 


  1. 1.
    Durham TA, Turner JR (2008) Introduction to statistics in pharmaceutical clinical trials. Pharmaceutical Press, LondonGoogle Scholar
  2. 2.
    Turner JR (2010) Integrated cardiovascular safety: employing a three-component risk exclusion model in the assessment of investigational drugs. Appl Clin Trials June issue:76–79Google Scholar
  3. 3.
    ICH Guidance E14, The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.
  4. 4.
    Turner JR, Satin LZ, Callahan TS, Litwin JS (2010) The science of cardiac safety. Appl Clin Trials 19(Suppl 11):4–8, 14Google Scholar
  5. 5.
    FDA (2008) Guidance for industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat Type 2 diabetes.
  6. 6.
    EMA (2010) Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus (Draft).
  7. 7.
    Turner JR, Somaratne R, Cabell CH, Tyner CA (2011) Centralized endpoint adjudication in cardiovascular outcomes studies: composite endpoints, risk ratios, and clinical endpoint committees. J Clin Stud 3:46–49Google Scholar
  8. 8.
    Caveney E, Turner JR (2010) Regulatory landscapes for future antidiabetic drug development (Part I): FDA guidance on assessment of cardiovascular risks. J Clin Stud January issue:34–36Google Scholar

Copyright information

© The Author (s) 2011

Authors and Affiliations

  1. 1.Cardiac Safety ServicesQuintilesDurhamUSA

Personalised recommendations